11.53
-0.19 (-1.58%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | ARS Pharmaceuticals, Inc. | Bullish | Bullish |
Stockmoo Score
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Cantor Fitzgerald, 160.30%) | Buy |
| Median | 26.00 (125.60%) | |
| Low | 22.00 (Raymond James, 90.89%) | Buy |
| Average | 26.00 (125.60%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 13.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 16 Sep 2024 | 30.00 (160.30%) | Buy | 12.95 |
| 09 Sep 2024 | 30.00 (160.30%) | Buy | 11.71 | |
| Raymond James | 13 Aug 2024 | 22.00 (90.89%) | Buy | 13.06 |
| 25 Jul 2024 | 18.00 (56.18%) | Buy | 11.19 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |